

## Aldeyra Therapeutics Inc

### CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 15-Dec-2014

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)

# ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 6

Product Portfolio Drug Pipeline Detail..... 9

    Phase 1 Clinical..... 10

    Discovery..... 11

[Return to Table of Contents](#)

# Aldeyra Therapeutics Inc

## COMPANY OVERVIEW

|                                       |   |
|---------------------------------------|---|
| Company Name                          | Aldeyra Therapeutics Inc  |
| Parent Company Name                   | Aldeyra Therapeutics Inc  |
| Website                               | http://www.aldeyra.com/   |
| Country                               | US  |
| Number of Drugs in Active Development | 2   |
| Number of Inactive Drugs              | 1   |
| Number of Patents as Owner            | 6   |
| Number of Patents as Third Party      | 0   |
| Number of Deals                       | 1   |
| Key Indications                       | Uveitis, Autosomal recessive disorder, Macular degeneration, Age related macular degeneration, Atherosclerosis, Atopic dermatitis, Cataract, Diabetes mellitus, Metabolic syndrome X, Parkinsons disease, Retinopathy, Rheumatoid arthritis, Sepsis, Stargardt disease, Toxicity                        |
| Key Target-based Actions              | Unspecified receptor antagonist, CXC9 chemokine ligand inhibitor, IL-12 antagonist, IL-17 antagonist, IL-5 antagonist, Interleukin-1 beta ligand inhibitor, Leukemia inhibitory factor antagonist, Mitochondrial intermediate peptidase inhibitor, Monocyte chemotactic protein 1 ligand inhibitor, TNF |
| Key Technologies                      | Small molecule therapeutic, Ophthalmic formulation, Ophthalmic liquid formulation, Dermatological formulation, Emulsion dermatological, Transdermal formulation, Condensational synthesis, Nucleophilic substitutional synthesis, Salt synthesis  |

## COMPANY PROFILE

### SUMMARY

Aldeyra Therapeutics Inc (formerly Aldexa Therapeutics Inc; Neuron Systems Inc), a biotechnology company incorporated in 2004, focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules.

### FINANCIAL

In June 2014, the company was added to the Russell Microcap Index.

In May 2014, Aldeyra was to raise gross proceeds of \$12 million from an IPO of 1.5 million common stock shares priced at \$8 each. The underwriters were granted a 45-day overallotment option to purchase up to 225,000 additional common stock shares. At that time, the shares began trading on the NASDAQ Capital Market under the ticker symbol 'ALDX'. The offering closed later that month and the company raised net proceeds of \$11 million.

[Return to Table of Contents](#)




# PRODUCT PORTFOLIO SUMMARY

## DRUGS

### Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

| Indication           | Active | Inactive | Total |
|----------------------|--------|----------|-------|
| Ocular disease       | 1      | 1        | 2     |
| Genetic disorder     | 1      | 0        | 1     |
| Inflammatory disease | 1      | 0        | 1     |

[Return to Table of Contents](#)

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

| Development Status      | Number of Drugs |
|-------------------------|-----------------|
| Phase 1 Clinical        | 1               |
| Discovery               | 1               |
| No Development Reported | 1               |

## CLINICAL TRIALS

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

| Indication             | As Owner | As Third Party | Total |
|------------------------|----------|----------------|-------|
| Cardiovascular disease | 1        | 0              | 1     |
| Endocrine disease      | 1        | 0              | 1     |

[Return to Table of Contents](#)

|                           |   |   |   |
|---------------------------|---|---|---|
| Gastrointestinal disease  | 1 | 0 | 1 |
| Immune disorder           | 1 | 0 | 1 |
| Musculoskeletal disease   | 1 | 0 | 1 |
| Ocular disease            | 6 | 0 | 6 |
| Metabolic disorder        | 1 | 0 | 1 |
| Neurological disease      | 1 | 0 | 1 |
| Infectious disease        | 1 | 0 | 1 |
| Toxicity and intoxication | 1 | 0 | 1 |
| Inflammatory disease      | 1 | 0 | 1 |
| Dermatological disease    | 1 | 0 | 1 |

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



## PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### NS-2 (eye drops, uveitis), Aldeyra

#### NS-2 (eye drops, uveitis), Aldeyra SNAPSHOT

|                      |   |
|----------------------|---|
| Drug Name            | NS-2 (eye drops, uveitis), Aldeyra  |
| Key Synonyms         |   |
| Originator Company   | Aldeyra Therapeutics Inc  |
| Active Companies     | Aldeyra Therapeutics Inc  |
| Inactive Companies   |   |
| Highest Status       | Phase 1 Clinical  |
| Active Indications   | Uveitis   |
| Target-based Actions |   |
| Other Actions        | Unspecified drug target;Anti-inflammatory                                       |
| Technologies         | Ophthalmic formulation;Ophthalmic liquid formulation;Small molecule therapeutic |
| Last Change Date     | 05-Aug-2014   |

#### NS-2 (eye drops, uveitis), Aldeyra DEVELOPMENT PROFILE

##### SUMMARY

Aldeyra Therapeutics is developing NS-2, which binds and traps free aldehydes, as an eye drop formulation, for the potential treatment of acute anterior uveitis. By May 2014, a phase I trial had been completed. At that time, additional clinical trials were planned for 2014. In August 2014, the company expected filing an IND by the end of 2014. In June 2014, data from the clinical trials were expected in 2015.

#### NS-2 (eye drops, uveitis), Aldeyra DEVELOPMENT STATUS

##### CURRENT DEVELOPMENT STATUS

| Company                  | Indication | Country | Development Status | Date        |
|--------------------------|------------|---------|--------------------|-------------|
| Aldeyra Therapeutics Inc | Uveitis    | US      | Phase 1 Clinical   | 01-May-2014 |

#### NS-2 (eye drops, uveitis), Aldeyra DRUG NAMES

| Names                              | Type          |
|------------------------------------|---------------|
| NS-2 (eye drops, uveitis), Aldeyra |               |
| NS-2                               | Research Code |

[Return to Table of Contents](#)



## NS-2 (topical cream formulation, Sjogren-Larsson Syndrome), Aldeyra Therapeutics

### NS-2 (topical cream formulation, Sjogren-Larsson Syndrome), Aldeyra Therapeutics SNAPSHOT

|                             |   |
|-----------------------------|---|
| <b>Drug Name</b>            | NS-2 (topical cream formulation, Sjogren-Larsson Syndrome), Aldeyra Therapeutics                      |
| <b>Key Synonyms</b>         |   |
| <b>Originator Company</b>   | Aldeyra Therapeutics Inc  |
| <b>Active Companies</b>     | Aldeyra Therapeutics Inc  |
| <b>Inactive Companies</b>   |   |
| <b>Highest Status</b>       | Discovery   |
| <b>Active Indications</b>   | Autosomal recessive disorder  |
| <b>Target-based Actions</b> |   |
| <b>Other Actions</b>        | Anti-inflammatory;Unspecified drug target   |
| <b>Technologies</b>         | Transdermal formulation;Dermatological formulation;Emulsion dermatological;Small molecule therapeutic |
| <b>Last Change Date</b>     | 05-Aug-2014   |

### NS-2 (topical cream formulation, Sjogren-Larsson Syndrome), Aldeyra Therapeutics DEVELOPMENT PROFILE

#### SUMMARY

Aldeyra Therapeutics Inc is investigating NS-2, which binds and traps free aldehydes, as a topical cream formulation for the potential treatment of Sjogren-Larsson Syndrome. In May 2014, clinical trials were planned for 2014,. In August 2014, the company expected filing an IND by the end of 2014. In June 2014, data from the clinical trials were expected in 2015.

### NS-2 (topical cream formulation, Sjogren-Larsson Syndrome), Aldeyra Therapeutics DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

| Company                  | Indication                   | Country | Development Status | Date        |
|--------------------------|------------------------------|---------|--------------------|-------------|
| Aldeyra Therapeutics Inc | Autosomal recessive disorder | US      | Discovery          | 01-May-2014 |

### NS-2 (topical cream formulation, Sjogren-Larsson Syndrome), Aldeyra Therapeutics DRUG NAMES

| Names  | Type          |
|--|---------------|
| NS-2 (topical cream formulation, Sjogren-Larsson Syndrome), Aldeyra Therapeutics |               |
| NS-2   | Research Code |

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

